Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lower Extremity Arterial Disease Clear all
Terminated No phase listed Observational

REvascularization RateS and Clinical OUtcomes With DABRA Laser. A Long-Term 2-year Study

NCT04010045
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Endovascular Treatment of PAD
Device
Lead sponsor
Ra Medical Systems
Industry
Eligibility
22 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 18, 2026, 8:53 AM EDT
Suspended Not applicable Interventional

FRAME, External Support for Lower Limb Autologous Grafts

NCT04003480
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Artery Disease
Interventions
FRAME
Device
Lead sponsor
Vascular Graft Solutions Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 18, 2026, 8:53 AM EDT
Withdrawn Phase 3 Interventional

Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

NCT02433587
View directory record Official record
Conditions
Peripheral Arterial Disease, Endovascular Procedures
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Not applicable Interventional Results available

SuperNOVA Clinical Stenting Trial

NCT01292928
View directory record Official record
Conditions
Atherosclerosis of Native Arteries of the Extremities, Unspecified
Interventions
Stent implantation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
28
States / cities
Birminham, Alabama • Los Angeles, California • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 18, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

NCT06437028
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care
Other
Lead sponsor
Samaritan Biologics
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroe, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Loco-Regional Liposomal Bupivacaine Injection

NCT05992896
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Bupivacaine liposome, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 18, 2026, 8:53 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

NCT07290673
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
FoundationDRS Solo, Standard of Care
Other
Lead sponsor
Samaritan Biologics
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional

Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries

NCT07353905
View directory record Official record
Conditions
Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions
Intravascular Ultrasound (IVUS), Angiographic-guided Intervention
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Dallas, Texas • Fort Worth, Texas • McKinney, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Not applicable Interventional Results available

A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.

NCT05145439
View directory record Official record
Conditions
Diabetic Foot Ulcer, Peripheral Arterial Disease, Wound; Foot
Interventions
VibratoSleeve Therapeutic Ultrasound Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Phase 3 Interventional

Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])

NCT00693940
View directory record Official record
Conditions
Peripheral Vascular Diseases, Cardiovascular Diseases
Interventions
Group mediated cognitive behavioral (GMCB) sessions, Health education sessions
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
25 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions
Ad2/HIF-1α/VP16, Saline (Placebo Control)
Biological · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Peripheral Arterial Disease

NCT03251391
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Cardiac Rehabilitation Program, Conventional Therapy
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 18, 2026, 8:53 AM EDT
Terminated Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059644
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Early Phase 1 Interventional

Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD

NCT02756884
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
LoFU and aADSC, adipose derived stem cells
Biological
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 18, 2026, 8:53 AM EDT
Not listed Not applicable Interventional Results available

PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT03970538
View directory record Official record
Conditions
Critical Limb Ischemia, Critical Lower Limb Ischemia, Peripheral Artery Disease, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Arterial Occlusive Diseases, Arterial Occlusion, Arterial Disease, Peripheral Artery Occlusion, Peripheral Vascular Disease, Peripheral Ischemia, Vascular Diseases
Interventions
LimFlow System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
San Francisco, California • Torrance, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 18, 2026, 8:53 AM EDT
Not listed Not applicable Interventional

External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality

NCT02054416
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ArtAssist© Device
Device
Lead sponsor
Temple University
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 18, 2026, 8:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Noxsano Wound Care Bandage

NCT04123093
View directory record Official record
Conditions
Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions
Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care)
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Not applicable Interventional Results available

Heat Therapy to Reduce Pain and Improve Walking Tolerance

NCT03435835
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Control/Sham Treatment, Heat Therapy (HT)
Device
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 18, 2026, 8:53 AM EDT
Recruiting No phase listed Observational

Diabetic Neuropathy in Spinal Cord Stimulator Patients

NCT04687215
View directory record Official record
Conditions
Diabetes Mellitus, Neuropathy, Neuropathic Pain, Vascular Diseases, Vascular Stiffness, Microvascular Changes, Pain, Chronic
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374, Placebo Matching
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 8:53 AM EDT
Completed No phase listed Observational Results available

Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

NCT04229563
View directory record Official record
Conditions
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
Interventions
AURYON Atherectomy System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Davenport, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 18, 2026, 8:53 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059657
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2006 · Synced Oct 18, 2026, 8:53 AM EDT